Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma, Follicular 10Lymphoma 9Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 2Recurrence 2Lymphoma, T-Cell, Peripheral 2Hodgkin Disease 2Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Hematopoietic and Lymphoid System Neoplasm 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Bendamustine Hydrochloride × Clear all
NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutchinson Cancer Center

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡